Physician

Mark D Harris, M.D.

According to 2025 Medicare claims, Mark Harris, M.D. (NPI: 1437157872) practices rheumatology in the Wilmington, NC market, with the plurality of this provider's patient population coming from New Hanover, NC. This provider's primary affiliated billing organization is CAROLINA ARTHRITIS ASSOCIATES, P.A. (NPI: 1427010081; TIN: 561745946) and primary practice location at 28401-6442.

Harris' data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 695 traditional Medicare patients, billed 296,175 HCPCS/CPT codes, and received $3,350,781 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 2,254 prescription claims across 359 beneficiaries totaling $1,378,764 in drug costs, led by Humira(Cf) Pen (Adalimumab). 2018 DME data shows 12 claims. Open Payments data shows 28 records totaling $6,814. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has changed little. Similarly, Part D prescription costs have changed little. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	609	124,652	$2,263,450
2016	608	172,259	$2,574,337
2017	577	162,053	$2,875,638
2018	574	144,301	$2,811,831
2019	565	151,064	$2,996,088
2020	635	167,486	$3,239,511
2021	675	191,594	$3,030,318
2022	628	201,843	$3,002,659
2023	624	245,961	$3,016,272
2024	695	296,175	$3,350,781

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	401	4,022	$908,418
2016	403	3,768	$1,037,837
2017	411	3,560	$1,090,189
2018	419	3,674	$1,213,785
2019	412	3,260	$1,004,535
2020	422	3,156	$1,087,721
2021	379	2,602	$1,105,136
2022	331	2,259	$1,337,777
2023	319	1,982	$1,178,104
2024	359	2,254	$1,378,764

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	23	25	$1,170
2016	N/R	N/R	N/R
2017	N/R	14	$209
2018	N/R	12	$183
2019	N/R	N/R	N/R
2020	N/R	N/R	N/R
2021	N/R	N/R	N/R
2022	N/R	N/R	N/R
2023	N/R	N/R	N/R
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	498	1,130	$88
80076	Liver function blood test panel	420	1,141	$8
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	483	1,262	$8
86140	Measurement c-reactive protein for detection of infection or inflammation	460	1,201	$5
82565	Blood creatinine level	500	1,260	$5

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Humira(Cf) Pen	Adalimumab	36	1,036	$354,336
Humira(Cf)	Adalimumab	13	588	$134,076
Xeljanz	Tofacitinib Citrate	14	540	$101,135
Xeljanz Xr	Tofacitinib Citrate	12	420	$77,820
Hizentra	Immun Glob G(Igg)/Pro/Iga 0-50	26	728	$73,157

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	9	$268	Janssen Biotech, Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	19	$6,546	Eli Lilly and Company
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Mark D. Harris, M.D.?

Tedicare shows public-source Medicare data for Mark D. Harris, M.D. (NPI 1437157872), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Mark D. Harris, M.D. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Mark D. Harris, M.D.?

Mark D. Harris, M.D. is linked to CAROLINA ARTHRITIS ASSOCIATES, P.A. (billing NPI 1427010081) in the available physician profile data.

Does Mark D. Harris, M.D. have Open Payments data?

Mark D. Harris, M.D. has 28 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.